The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04481282|
Recruitment Status : Recruiting
First Posted : July 22, 2020
Last Update Posted : July 22, 2020
|Condition or disease||Intervention/treatment||Phase|
|Immune Thrombocytopenia||Drug: Terbutaline Drug: Danazol||Phase 2|
Immune thrombocytopenia (ITP) is a severe bleeding disorder. Approximately 2/3 of patients achieve remission from first-line therapies. However, the underlying mechanism of corticosteroid-resistant or relapsed ITP is not well understood; thus, treatment remains a great challenge. β2-AR agonist terbutaline modulates T cell differentiation and effector cell function.
A single center prospective study was performed in non-splenectomized ITP patients who were either resistant to a standard dose of corticosteroids or had relapsed. Patients were assigned to terbutaline plus danazol group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study, in order to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid-resistant/relapsed ITP.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia|
|Actual Study Start Date :||July 8, 2020|
|Estimated Primary Completion Date :||March 31, 2021|
|Estimated Study Completion Date :||July 31, 2021|
Experimental: Terbutaline plus Danazol group
Terbutaline 2.5mg tid po plus danazol 200mg bid po for 12weeks
2.5mg po tid for 12 weeks
Other Name: Bricanyl Brethine
200mg po bid for 12 weeks
- Sustained response [ Time Frame: 6 months ]The maintenance of platelet count ≥ 30 x 10^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-month follow-up. Interim analysis was scheduled at 50% through recruitment.
- complete remission [ Time Frame: 6 months ]The number of participants (responders) with platelet count>=100x10^9/L (CR) and the absence of bleeding.
- partial remission [ Time Frame: 6 months ]The number of participants (responders) with platelet count >=30x10^9/L and at least a 2-fold increase in the baseline count (PR) without the administration of any other platelet increasing therapy.
- time to response [ Time Frame: 6 months ]Time to response was defined as the time from starting treatment to the time to achieve the response. Interim analysis
- duration of response [ Time Frame: 6 months ]Duration of response was measured from the achievement of response to the loss of response.
- incidence of treatment-emergent adverse events [ Time Frame: 6 months ]Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04481282
|Contact: Xiaohui Zhang, MDfirstname.lastname@example.org|
|Contact: Gaochao Zhang, phDemail@example.com|
|Peking University Insititute of Hematology, Peking University People's Hospital||Recruiting|
|Beijing, Beijing, China, 100010|
|Contact: Xiaohui Zhang firstname.lastname@example.org|
|Principal Investigator:||Xiaohui Zhang, MD||Peking University People's Hospital, Peking University Insititute of Hematology|